Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07788989 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Predict Atrial Fibrillation (AF) Burden in Participants With PAF and PsAF Treated With the VARIPULSE™ PFA Catheter

Study acronym: SPECTRA-AF
StatusNot Yet Recruiting
PhaseNot applicable
Started2026-10-30
View on ClinicalTrials.gov ↗
The purpose of this study is to evaluate how safe VARIPULSE™ Catheter is and how well it works in the treatment of participants with symptomatic paroxysmal atrial fibrillation (PAF; irregular heartbeat where episodes start and stop on their own, usually within seven days) and symptomatic persistent atrial fibrillation (PsAF; irregular, rapid heartbeat that lasts more than 7 days and doesn't stop on its own).

Amendment history 7 changes detected by DataLookout

2026-09-16
Trial status changed: Withheld → Not Yet Recruiting
2026-09-16
Phase changed: not specified → not applicable
2026-09-16
Primary endpoint(s) modified
2026-09-16
Enrollment changed: None → 2300
2026-09-16
Sponsor changed: [Redacted] → Biosense Webster, Inc.
Was[Redacted]
NowBiosense Webster, Inc.
2026-09-16
Trial arms changed: 0 → 2
2026-09-16
Interventions modified
Trial Details
NCT Number NCT07788989
Lead Sponsor Biosense Webster, Inc.
Conditions Atrial Fibrillation
Enrollment 2,300 participants
Start Date 2026-10-30
Primary Completion 2029-10-31 (estimated)
Study Completion 2029-10-31 (estimated)
Updated on ClinicalTrials.gov 2026-09-15